Om

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. The company’s current pipeline centers on three antibody-based programs: rosnilimab, designed to selectively deplete pathogenic T cells; ANB033, an anti-CD122 antagonist being studied in immune-mediated conditions such as celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells. Its work is concentrated in research and development, with a focus on advancing therapies that address immune pathway dysfunction across rheumatology and gastroenterology settings. First Tracks Biotherapeutics, Inc. operates as a specialized player in the biotechnology market, contributing to the broader development of targeted treatments for complex inflammatory disorders.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I FIRST TRACKS BIOTHERAPEUTICS MED ENDAVU: Køb First Tracks Biotherapeutics ($TRAXV) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i First Tracks Biotherapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.